Stockreport
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
TheFly reported on January 22 that Jefferies downgraded FOLD to Buy from Hold and lowered the price target to $14.50 from $16. The company got substantial pharmaceutical takeover interest outside of BioMarin, according to proxy records, but Jefferies does not expect any more proposals. Separately, last month on December 19, BioMarin announced that it will acquire Amicus Therapeutics, Inc. (NASDAQ:FOLD) for $14.50 per share in an all-cash transaction, valuing the company at approximately $4.8 billion. The acquisition adds two marketed therapies that are Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, which generated $599 million in combined revenue over the past four quarters. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotechnology company that us focused on developing and commercializing innovative treatments for rare and orphan diseases. Its pipeline includes therapies for genetic and metabolic disorders, such as Fabry disease, leveraging precision scien
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Piper Sandler from $122.00 to $84.00. They now have an "overweight" rating on the stock.[MarketBeat]
- Should You Buy BioMarin Pharmaceutical Before Feb. 18? [Yahoo! Finance][Yahoo! Finance]
- BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility[PR Newswire]
- BioMarin's Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach [Yahoo! Finance][Yahoo! Finance]
- BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $80.00 price target on the stock.[MarketBeat]
- More
BMRN
SEC Filings
SEC Filings
- 1/29/26 - Form 8-K
- 1/26/26 - Form 8-K
- 1/22/26 - Form 4
- BMRN's page on the SEC website
- More